Abbott Laboratories (ABT) 10-K Summaries & Annual Filing History
Review Abbott Laboratories (ABT) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Abbott Laboratories reported increased revenue and strong operating cash flow in its latest annual filing. The company's financial performance reflected growth across its diversified healthcare businesses.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$44.3B
Revenue reported for the fiscal year.
Operating income
$8.1B
Income from operations reported for the year.
Net income
$6.5B
Net income reported for the year.
Operating cash flow
$9.6B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $43.7B | +1.3% |
| Dec 31, 2023 | $40.1B | -8.1% |
| Dec 31, 2024 | $42B | +4.6% |
| Dec 31, 2025 | $44.3B | +5.7% |
Business overview
Abbott Laboratories is a diversified healthcare company operating through segments including diagnostics, medical devices, nutrition, and established pharmaceuticals. The filing describes its business overview and risk factors, including cybersecurity and unresolved staff comments. The company serves global markets with a broad portfolio of health products and technologies.
Financial performance
Revenue for the period was reported at the level shown in the filing metrics, with operating income and net income also presented. The trend data shows revenue has fluctuated over recent years, with the latest period reflecting an increase. Operating cash flow was reported at a substantial figure, indicating strong cash generation from operations.
Material risks
The filing identifies risk factors in Item 1A, which may include operational, regulatory, or competitive uncertainties common in the healthcare industry. Specific risks mentioned in the context include unresolved staff comments and cybersecurity concerns. No additional material risks beyond those stated in the supplied filing context are identified.
Liquidity and capital
The filing includes Management’s Discussion and Analysis of Financial Condition and Results of Operations, which likely discusses liquidity and capital allocation themes. However, no specific capital allocation decisions or liquidity details beyond the reported metrics are supplied in the provided context.
What to watch
Monitor how the company addresses the unresolved staff comments and cybersecurity risk factors in its next filing.